^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

TNFA elevation

i
Other names: Tumor Necrosis Factor, Tumor Necrosis Factor Ligand Superfamily Member 2, Cachectin, TNF-Alpha, TNFSF2, TNF-A, TNFA, Tumor Necrosis Factor (TNF Superfamily, Member 2), Tumor Necrosis Factor Ligand 1F, Tumor Necrosis Factor-Alpha, TNF Superfamily, Member 2, TNF Macrophage-Derived, TNF Monocyte-Derived, APC1 Protein, TNLG1F
Entrez ID:
Related biomarkers:
1m
Bovine papillomavirus gene expression and inflammatory pathway activation vary between equine sarcoid tumour subtypes. (PubMed, Vet Immunol Immunopathol)
Results for BPV viral load and gene expression differed from previous reports and are insufficient to explain the spectrum of tumour phenotypes. Activation of both pro-inflammatory and anti-inflammatory immune pathways in sarcoids could influence tumour growth and effective immune responses, and the contribution of specific infiltrating immune cells requires further investigation.
Journal
|
IL6 (Interleukin 6) • ATR (Ataxia telangiectasia and Rad3-related protein) • IL10 (Interleukin 10) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • TLR9 (Toll Like Receptor 9) • TGFB1 (Transforming Growth Factor Beta 1) • IL1B (Interleukin 1, beta) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA)
|
TNFA elevation • TLR9 expression
11ms
Protective effect of TNFAIP3 on testosterone production in Leydig cells under an aging inflammatory microenvironment. (PubMed, Arch Gerontol Geriatr)
TNFAIP3 exhibits inhibitory effects on apoptosis and promotes testosterone production in Leydig cells. The protective influence of TNFAIP3 on Leydig cells within an inflammatory microenvironment is likely mediated through by inhibiting the P38MAPK pathway and upregulating CEBPB expression.
Journal
|
TNFAIP3 (TNF Alpha Induced Protein 3)
|
TNFA elevation • TNFAIP3 overexpression
1year
Genome Wide siRNA Screen Identifies CGAS-Sting Pathway As a Pharmacological Target That Promotes Survival of Hematopoietic Stem Cells Deficient in Fanconi Genes (ASH 2023)
Other proposed therapies including TGF-b, metformin, and resveratrol have met with limited clinical success...The elevated pIRF3 levels were further increased upon addition of mitomycin C (MMC) in FA mutant cells as compared to gene corrected cells... It has previously been shown that FA patients have elevated TNF-alpha, IFN-gamma levels, and NFkbactivation, and interferon alpha administration hastens the onset of bone marrow failure in FA patients. Our results show that FA mutant cells have elevated CGAS-STING signaling resulting in heightened interferon gene expression. Elevated R-loop levels in FA cells act as trigger for the CGAS-STING pathway.
IO biomarker
|
IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • FANCA (FA Complementation Group A) • CD34 (CD34 molecule) • FANCD2 (FA Complementation Group D2) • IRF7 (Interferon Regulatory Factor 7)
|
TNFA elevation
|
mitomycin • metformin
over1year
TAK-243 increases tumor immunogenicity enhancing systemic anti-tumor immune response and tumor regression in combination with immune checkpoint inhibition in a syngeneic model of lymphoma (AACR 2023)
Furthermore, re-inoculation of subjects that exhibited complete regression of tumor masses with A20 cells showed no growth of new tumors. Taken together, these data suggest that intratumor injection of TAK-243 has potential to act as an in situ vaccine which increases anti-tumor immunogenicity and primes tumors for response to ICIs.
Combination therapy • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • TNFA (Tumor Necrosis Factor-Alpha) • GZMB (Granzyme B)
|
TNFA elevation • GZMB elevation
|
TAK-243
2years
Over expression of mTOR gene predicts overall survival in myelodysplastic syndromes. (PubMed, Mol Biol Rep)
Our study showed an elevation of TNF and AMPK signalling pathways in MDS. TNF signalling might be mediating the proliferative advantage to myeloid clonal cells (mutation carrying cells) over normal cells, whereas, AMPK signalling could be acting as protector against it (favouring normal cells). Hence it would be interesting to explore the functions and pathways associated with mTOR, AMPK, MAPK8 and JUNB in myelopoiesis related diseases like MDS.
Journal
|
mTOR (Mechanistic target of rapamycin kinase) • ASXL1 (ASXL Transcriptional Regulator 1) • CD34 (CD34 molecule) • JUNB (JunB Proto-Oncogene AP-1 Transcription Factor Subunit) • MAPK8 (Mitogen-activated protein kinase 8)
|
ASXL1 mutation • TNFA elevation • MTOR overexpression
2years
Clinical and Basic Evaluation of the Effects of Upregulated TNFAIP3 Expression on Colorectal Cancer. (PubMed, Dis Markers)
Our evidences suggest the promising potential of utilizing TNFAIP3 and NFκB as important reference indices for determining the prognostic outcome of CRC. Furthermore, we revealed that TNFAIP3 overexpression inhibited CRC cell proliferation, invasion, and migration.
Journal
|
TNFAIP3 (TNF Alpha Induced Protein 3)
|
TNFA elevation • TNFAIP3 overexpression
over3years
Weakly Acidic Bile Is a Risk Factor for Hypopharyngeal Carcinogenesis Evidenced by DNA Damage, Antiapoptotic Function, and Premalignant Dysplastic Lesions In Vivo. (PubMed, Cancers (Basel))
Weakly acidic pH increases the risk of bile-related hypopharyngeal neoplasia. The oncogenic properties of biliary esophageal reflux on the epithelium of the upper aerodigestive tract may not be fully modified when antacid therapy is applied. We believe that due to bile content, alternative therapeutic strategies using specific inhibitors of relevant molecular pathways or receptors may be considered in patients with refractory GERD.
Journal • IO biomarker
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • MIR155 (MicroRNA 155) • MIR21 (MicroRNA 21)
|
BCL2 overexpression • BCL2 expression • TNFA elevation • miR-21 overexpression
over4years
[VIRTUAL] Combining irreversible electroporation with TLR7 and CD40 agonists confers systemic anti-tumor immunity in a murine pancreatic cancer model (AACR-II 2020)
These data suggest that local delivery of CD40Ab and TLR7 agonists augment the systemic immune effects of IRE and have the potential to improve the overall survival of patients undergoing IRE for locally advanced PC by reducing distant recurrence.
Preclinical • Tumor Mutational Burden • IO biomarker
|
TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • CD44 (CD44 Molecule) • IL2 (Interleukin 2) • CD40 (CD40 Molecule)
|
TMB-L • TNFA elevation